Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers

http://www.businessweek.com/ap/2012-11-27/eu-reviews-cancer-drug-from-merck-and-endocyte

AP News

EU reviews cancer drug from Merck and Endocyte


NEW YORK (AP) — Merck & Co. and Endocyte Inc. said Tuesday that European Union regulators will review their drug vintafolide as a treatment for ovarian cancer.

The companies said the European Medicines Agency will review vintafolide as a treatment for ovarian cancer that is resistant to platinum-based chemotherapy. The agency will also review their application for a diagnostic agent that is intended to help identify patients who could benefit from the drug.

Vintafolide is designed to target a folate receptor that appears on cancer cells but doesn't exist on most other cells. Endocyte, based in West Lafayette, Ind., said the receptor is found on 80 to 90 percent of ovarian and lung cancers.

Vintafolide and the diagnostic agent both have orphan drug status, which means competing products will be barred from the market for up to 10 years if they are approved.

Whitehouse Station, N.J.-based Merck will pay Endocyte $5 million because the application was accepted.

Merck stock fell 9 cents to $44.10 and Endocyte shares lost 15 cents to $8.99 in midday trading Tuesday.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus